HERA study: A study of Intravenous R597 (Trastuzumab) in Women with HER2-Positive Primary Breast Cancer
Phase 3
- Conditions
- Breast Cancer
- Registration Number
- JPRN-jRCT2080220185
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Female patients, >=18 years of age, with HER2-positive primary breast cancer;
Completion of adjuvant systemic chemotherapy and radiotherapy, if applicable.
Exclusion criteria:
History of prior invasive breast cancer;
Prior use of any anti-HER2 therapy.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method